PARP Inhibitors in the Management of Ovarian Cancer
Treatment
Repeating PARPi
Recommendation 1.0
Newly Diagnosed Ovarian Cancer
Recommendation 2.0
Rapid Update – Recommendation 2.1
Recommendation 2.2
Recommendation 2.3
(B/H ratio unknown)
Recurrent Ovarian Cancer - Second-line or Greater Maintenance and Treatment
Rapid Update – Recommendation 3.0
- Options include: olaparib 300 mg every 12 hours, rucaparib 600 mg every 12 hours or niraparib 200–300 mg once daily.
Rapid Update – Recommendation 3.1/3.2
Rapid Update – Recommendation 3.3
PARPi in Combination
Recommendation 4.0
Management of Adverse Events
Recommendation 5.0 Anemia
Recommendation 5.1 Neutropenia:
Recommendation 5.2 Platelets:
Recommendation 5.3 Persistent cytopenia:
Recommendation 5.4 Nausea:
Recommendation Grading
Overview
Title
PARP Inhibitors in the Management of Ovarian Cancer
Authoring Organization
American Society of Clinical Oncology
Publication Month/Year
September 23, 2022
Last Updated Month/Year
October 1, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Target Patient Population
Patients with ovarian cancer
Inclusion Criteria
Female, Adolescent, Adult, Older adult
Health Care Settings
Ambulatory, Hospital, Outpatient, Radiology services
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Treatment, Management
Diseases/Conditions (MeSH)
D010051 - Ovarian Neoplasms, D010049 - Ovarian Diseases, D010048 - Ovarian Cysts, D000077216 - Carcinoma, Ovarian Epithelial, D000071137 - Poly (ADP-Ribose) Polymerase-1
Keywords
ovarian cancer, Epithelial Ovarian Cancer, Advanced Ovarian Cancer, PARP Inhibitors, PARP
Source Citation
Tew W, Lacchetti C, Kohn E, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. [published online ahead of print, 2022 Sep 23]. doi: 10.1200/JCO.20.01934
Tew W, Lacchetti C, Ellis A, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020;38(30):3468-3493. doi:10.1200/jco.20.01924